EDAP TMS Welcomes Joshua H. Levine to Board of Directors
EDAP TMS SA (Nasdaq: EDAP), a recognized leader in robotic energy-based therapies, has made a significant addition to its Board of Directors with the appointment of Joshua H. Levine. This strategic move marks a pivotal moment for the company as it continues to strengthen its position within the medical technology industry.
Expertise and Vision
Dr. Lance Willsey, Interim Chairman of the Board, expressed enthusiasm about Levine's addition, highlighting his extensive executive experience and a proven track record of fostering shareholder value. “Josh brings invaluable insights in medical technology, particularly as EDAP pushes forward with the Focal One robotic HIFU platform,” he stated. This innovative platform is designed to advance treatments, especially in the realm of prostate cancer therapies.
Transforming Treatment Paradigms
In his own words, Levine expressed excitement about joining EDAP at this transformative time. He noted the remarkable advancements of the Focal One platform over recent years, recognizing it as a leader in the field. Levine's expertise promises to play a crucial role in shaping EDAP’s strategic direction as they aim to broaden the technology's application to include conditions such as endometriosis and benign prostatic hyperplasia (BPH).
Diverse Experience in Medical Technology
Levine's career spans decades and includes high-profile roles that underscore his capability as a strategic business leader. He previously served as the President and CEO of Accuray Incorporated, where he led a successful turnaround that restored the company's growth and profitability. Before that, he played an influential role at Immucor, Inc. and Mentor Corporation, driving significant milestones in each organization's history.
Contributions to Board Governance
In addition to his operational achievements, Levine has a solid background in board governance, having served on various committees at Natus Medical Corporation. His experiences in managing corporate governance and strategic initiatives will be invaluable assets to EDAP TMS as it continues to innovate and expand its market reach.
About EDAP TMS SA
EDAP TMS SA stands at the forefront of the medical device sector with its advanced robotic energy-based therapies. The company is renowned for its development and distribution of minimally invasive medical devices that leverage ultrasound technology. The flagship product, the Focal One system, exemplifies their commitment to pioneering treatment solutions controlled by urologists, with potential applications extending beyond prostate cancer.
Reducing Treatment Times and Enhancing Outcomes
The Focal One platform is designed to provide superior precision in treatment delivery, which may lead to reduced recovery time and improved patient outcomes. With a focus on combining cutting-edge imaging and robotic technologies, EDAP TMS is positioned to remain a key player in the evolving landscape of medical therapies.
Contact Information
For more information regarding EDAP TMS and its innovations, interested parties can reach the company via investor relations. Blandine Confort oversees inquiries related to legal and investor matters, while John Fraunces of LifeSci Advisors provides direct support for investor communications.
Frequently Asked Questions
Who has recently joined the Board of Directors at EDAP TMS?
Joshua H. Levine has been appointed to the Board of Directors at EDAP TMS.
What is the primary focus of EDAP TMS?
EDAP TMS specializes in robotic energy-based therapies and innovative medical device solutions, particularly in the field of ultrasound technology.
How does the Focal One platform benefit prostate cancer treatment?
The Focal One platform provides a minimally invasive approach to prostate cancer treatment, enhancing precision and potentially improving patient recovery times.
What previous positions did Joshua H. Levine hold?
Levine served as the CEO of Accuray Incorporated and was involved with Immucor, Inc. and Mentor Corporation, holding leadership roles that drove significant company growth.
How can investors contact EDAP TMS for inquiries?
Investors can contact Blandine Confort for investor relations or John Fraunces at LifeSci Advisors for investment-related inquiries.
